Arab News

South Korea on the course of “Corona treatment” .. The tests are promising

It has a company "Celtron" South Korean experimental treatment that I developed for a disease "Coved 19", Has shown a 100-fold reduction in the viral load of the disease in animal experiments, saying it aims to start clinical trials in humans in late July.

Pharmaceutical companies around the world are rushing to develop treatments or vaccines for a disease that resembles itself flu, After killing more than 371,000 people globally.

And she said "Celtron" Her pre-clinical studies showed improved recovery from Ceylon symptoms the nose Cough and body pain, after the first day of treatment will eliminate Pneumonia Within 6 days.

The company and the Chengbuk National University Collaborating School of Medicine added in the study, in a statement, that the experiments were carried out on mongoose animals, and that they will be expanded to include mugs, mice and monkeys before clinical trials.

Kun Ki Sung, head of the company’s R&D unit "Celtron" For"Reuters", The company is considering conducting clinical trials in South Korea or abroad.

He added in the statement: "Celterion has the ability to produce large amounts of antibody therapy as soon as it is ready".

“>

The South Korean company, “Celtrion”, said that the experimental treatment it developed for “Covid 19” showed a reduction of 100 times the viral load of the disease in animal experiments, saying it aims to start clinical trials in humans in late July.

And pharmaceutical companies around the world are rushing to develop treatments or vaccines for the flu-like illness, after it has killed more than 371,000 people worldwide.

“Celterion” said that her study before the clinical phase showed an improved recovery from symptoms of runny nose, cough and body pain, after the first day of treatment and the elimination of pneumonia within 6 days.

The company and the Chengbuk National University Collaborating School of Medicine added in the study, in a statement, that the experiments were carried out on mongoose animals, and that they will be expanded to include mugs, mice and monkeys before clinical trials.

Kun Ki-sung, head of the research and development unit of the “Celetron” company, told Reuters that the company is studying clinical trials in South Korea or abroad.

He added, “(Celterion) has the ability to produce large quantities of antibody therapy as soon as it is ready.”

.


Source: Skynews

Tags
Show More

Related Articles

Back to top button
Close
Close